Skip to main content

Table 1 Rheumatoid arthritis-related parameters and traditional cardiovascular risk factors in subgroups of nondiabetic rheumatoid arthritis patients stratified by the presence of at least one new carotid plaque at follow-up enda

From: Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study

 

New carotid plaque formation during follow-up

Parameters

Yes

No

Patient demographics

  

   Total number of patients

19

45

   Age at follow-up end (years)b

70.6 ± 6.9

59.2 ± 12.1

   Sex, n (%)

14 women (73.7)

5 men (26.3)

39 women (86.7)

6 men (13.3)

   Months of follow-up (months)

40.6 ± 3.0

40.9 ± 3.0

RA-related parameters

  

   Duration of disease at follow-up end (years)

9.4 ± 3.9

11.9 ± 6.9

   Functional class of disease, n (%)

  

Class I

12 (63.2)

18 (40.0)

Class II

6 (31.6)

17 (37.8)

Class III

1 (5.3)

9 (20.0)

Class IV

0 (0)

1 (2.2)

   Stage of disease, n (%)

  

Early

6 (31.6)

11 (24.4)

Moderate

12 (63.2)

19 (42.2)

Severe

1 (5.3)

14 (31.1)

Terminal

0 (0)

1 (2.2)

   RF-positive, n (%)

13 (68.4)

29 (64.4)

   hs-CRP AUC during follow-up (mg/dl × months)

16.6 (12.4, 57.5)

23.8 (12.3, 45.2)

   ESR AUC during follow-up (mm/hour × months)

1,121.1 ± 627.6

1,157.0 ± 537.6

Disease-related treatments (months during follow-up)

  

   Nonbiologic DMARDs

38.4 (35.1, 41.4)

40.0 (32.6, 42.5)

   Biologic agents

0.0 (0.0, 39.3)

31.6 (0.0, 41.4)

   Corticosteroids

40.5 (35.2, 42.3)

33.2 (3.7, 41.7)

Remission during follow-up (months)

36.2 (32.4, 39.1)

31.4 (11.3, 37.3)

Remission during follow-up (% of follow-up time)

90.5 (85.0, 92.9)

84.6 (27.8, 92.6)

Traditional cardiovascular risk factors

  

   Hypertension at baseline, n (%)

12 (66.7)

17 (37.8)

   SBP AUC during follow-up (mmHg × months)

5,791.1 ± 634.3

5,416.7 ± 599.6

   DBP AUC during follow-up (mmHg × months)

3,491.4 ± 306.5

3,333.9 ± 323.9

   Antihypertensive treatment (% follow-up time)

2.3 (0, 2.4)

0 (0, 2.3)

   LDL ≥ 160 mg/dl and/or under statin treatment at baseline, n (%)

8 (42.1)

12 (26.7)

   LDL AUC during follow-up (mg/dl × months)

5,528.9 ± 1294.1

5,457.7 ± 1377.9

   Statin use during follow-up (% follow-up time)

0.0 (0.0, 29.0)

0.0 (0.0, 0.0)

   Smoking at end of follow-up, n (%)

7 (36.8)

14 (31.1)

   Total years of smoking

30 (0.0, 40.0)

0.0 (0.0, 29.0)

BMI (kg/m2)

  

   BMI at baseline

26.1 ± 3.5

25.9 ± 3.7

   BMI at follow-up end

26.0 ± 3.8

26.3 ± 4.4

   Positive family history of CAD, n (%)

7 (36.8)

8 (17.8)

Number of CV risk factors, n (%)

  

   0

0 (0)

13 (28.9)

   1

9 (47.4)

17 (37.8)

   2

7 (36.8)

12 (26.7)

   3

3 (15.8)

3 (6.7)

Carotid plaques at baseline, n (%)

14 (73.7)

16 (35.6)

  1. aAUC: area under the curve, BMI: body mass index, CAD: coronary artery disease, CV: cardiovascular, DBP: diastolic blood pressure, ESR: erythrocyte sedimentation rate, hs-CRP: high-sensitivity C-reactive protein, LDL: low-density lipoprotein, RA: rheumatoid arthritis, SBP: systolic blood pressure. Data are number (%), mean ± SD or median (lower and upper quartiles). bSignificant difference between subgroups after Bonferroni correction for multiple comparisons (P = 0.0084). All other comparisons did not reach significance.